or Try an Advanced Search...

    Regulus Therapeutics Stocks List

    Symbol Grade Name % Change
    PRQR A ProQR Therapeutics B.V. 6.57
    LPTX A LEAP THERAPEUTICS, INC. 0.00
    CAPR B Capricor Therapeutics, Inc. -3.23
    ABOS C Acumen Pharmaceuticals, Inc. -1.22
    SPRO F Spero Therapeutics, Inc. -4.07
    RGLS F Regulus Therapeutics Inc. 2.05
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Alnylam Pharmaceuticals Biotechnology Oligonucleotide Alzheimer's Disease Amyloid Amyloid Beta Amyloidosis Antimicrobial Resistance Atherosclerosis Bacterial Infections Biology Blastoma Cancer Carcinoma Cardiovascular Disease Cystic Fibrosis Disease Drug Resistant Bacterial Infections Evolutionary Biology

    Related ETFs - A few ETFs which own one or more of the above listed Regulus Therapeutics stocks.

    Symbol Grade Name Weight
    IBRN B iShares Neuroscience and Healthcare ETF 1.34
    IWC B iShares Microcap ETF 0.23
    IWO B iShares Russell 2000 Growth ETF 0.04
    IWN C iShares Russell 2000 Value ETF 0.03
    IWM B iShares Russell 2000 ETF 0.02
    View all Regulus Therapeutics ETFs...
    Compare ETFs
    Compare IBRN to IWO Compare IWN to IWM Compare IWO to IWM

        Regulus Therapeutics Stocks Recent News

        Date Stock Title
        Oct 31 ABOS Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference
        Oct 30 SPRO Spero’s stock slides after antibiotic flops in Phase II trial
        Oct 30 SPRO Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
        Oct 29 SPRO Spero to cut 39% of workforce on failed study, stock plunges 20%
        Oct 29 SPRO Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
        Oct 29 RGLS These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
        Oct 27 SPRO Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Alnylam Pharmaceuticals Biotechnology Oligonucleotide Alzheimer's Disease Amyloid Amyloid Beta Amyloidosis Antimicrobial Resistance Atherosclerosis Bacterial Infections Biology Blastoma Cancer Carcinoma Cardiovascular Disease Cystic Fibrosis Disease Drug Resistant Bacterial Infections Evolutionary Biology
        Regulus Therapeutics

        Regulus Therapeutics Inc. or Regulus (NASDAQ: RGLS) is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.

        More about Regulus Therapeutics
        Browse All Tags